Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04–012)

Autor:	T. Cosgriff, M. Min, T. Chidiac, M. Keaton, G. Harker, B. Mirtsching
Rok vydání:	2008
Předmět:	Oncology Cancer Research medicine.medical_specialty Taxane business.industry medicine.disease Metastatic breast cancer First line therapy Refractory Internal medicine Medicine Single agent In patient Injectable Suspension business Nab-paclitaxel
Zdroj:	Journal of Clinical Oncology. 26:1118-1118
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2008.26.15_suppl.1118
Popis:	1118 Background: Nab-paclitaxel for injectable suspension given weekly has shown activity in patients whose metastatic breast cancer was refractory to taxane therapy. The purpose of this phase II s...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::65a4a4ad53944b3c85a46b6ed96b87f3 https://doi.org/10.1200/jco.2008.26.15_suppl.1118 Zobrazit plný text záznamu